Clinical Trial Technology Opportunity Assessment

A senior director in R&D at an F100 pharma company wanted to conduct a landscape analysis of technology trends and innovation impacting Phase 3 clinical trials in immunology to improve speed, effectiveness, and patient/provider experience.

BTG delivered a digital health strategy consultant with 20+ years of diverse strategic advisory, market access, and competitive intelligence experience. The consultant had previously spearheaded a range of initiatives for top biopharma companies to inform digital health and launch strategies. On this project, the consultant identified key players and areas of opportunity, anticipated disruptive competitor developments, and pinpointed ways to achieve competitive advantage. The output delivered by the talent served to inform the digital health strategy for the Immunology R&D team.